Combating Antibiotic Resistant Bacteria: CARB Accelerator
ILSE along with Public Health Research Institute (PHRI) has made detailed plans and begun to construct a Biopharmaceutical Accelerator and is actively looking for funding and grant support for this endeavor. This accelerator when operational will be a unique organization to rapidly advance research in countering antibiotic research bacteria, which is growing to be one of the biggest challenges in the modern medical era. Working with a consortium of providers and a portfolio of third-party product opportunities, our vision for the ILSE- CARB Accelerator is to bring together the considerable strengths and existing capabilities of ILSE, ATCC-CTM and PHRI to generate innovative new products to combat antibiotic resistance. The CARB Accelerator will function as an R&D partner for product development companies with the goal of incentivizing innovation among its partners and network participants.
The CARB Accelerator will establish a proactive, structured process that offers a balanced risk portfolio of potential new therapeutic entities, diagnostic tools and new technologies. The Accelerator will fund products across a broad technology landscape (e.g. therapeutics, diagnostics, bacterial vaccines) so as to address current medical needs. Utilizing our extensive research experience and business acumen, we will identify and manage a portfolio of innovative projects portfolio to deliver compounds, biologics, vaccines, diagnostic tools and technologies that address the challenges presented by the emergence and spread of antibiotic resistance. Our plan is to establish and coordinate an enterprise network offering key services aimed to create a comprehensive approach with limited bureaucracy that will effectively accelerate drug advancement to the IND stage.